{"entity":{"id":"t-e-meds","kind":"company","name":"T-E Meds","aka":["T-E Meds, Inc.","T-E Meds Inc."],"tldr":"T-E Meds is a Taipei company that builds antibody-drug conjugates, antibodies that carry drugs to cancer cells, using linkers that hold several drug molecules at once. Its HER2 medicine TE-1182 carries two different cell-killing drugs and has orphan drug status for gastric cancer.","summary":"T-E Meds Inc., in Nangang District, Taipei, was established in 2022 as the second subsidiary of T-E Pharma Holding, according to the company. It uses a multi-arm linker platform to make drug bundles that are site-specifically conjugated to antibodies, producing homogeneous high drug-to-antibody-ratio antibody-drug conjugates and antibody-radionuclide conjugates; it says its candidates, for multiple myeloma, pancreatic cancer and HER2-related cancers, are in preclinical development. Its HER2 candidate TE-1182, made with CHO Pharma, carries both MMAF and exatecan on trastuzumab. On 6 October 2026 the FDA granted orphan drug designation for gastric cancer to a trastuzumab-MMAF/exatecan dual-payload antibody-drug conjugate sponsored by T-E Meds.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://www.temeds.com/"},{"label":"TE-1182","url":"https://www.temeds.com/te-1182/"},{"label":"FDA orphan designation, gastric cancer, 6 October 2026","url":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1145626"}],"tags":[],"related":[],"cancers":["gastric"],"sections":["adcs"],"technologies":["adc","dual-payload-adc"],"targets":["her2"],"drugs":["te-1182"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The company's anti-CD38 lenalidomide conjugate for multiple myeloma is not recorded as a product here. Read on 4 November 2026."],"hq":"Taipei","country":"TW","companyType":"biotech","website":"https://www.temeds.com/","founded":2022,"stage":"startup","investors":[],"funding":[]},"route":"/companies/t-e-meds/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"dual-payload-adc","kind":"technology","name":"Dual-payload ADC","route":"/technologies/dual-payload-adc/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"drug":[{"id":"te-1182","kind":"drug","name":"TE-1182","route":"/drugs/te-1182/"}]}}